Evidence-Grounded Agentic Formulation Development in an Autonomous Laboratory
Andromeda 2, an agentic laboratory system, reaches a 50% high-performance hit rate for paclitaxel SEDDS formulations versus 17% for its predecessor and 2% for DoE.
Andromeda 2 is an agentic system that reasons over structured in-house experimental evidence and invokes computational and experimental tools to design and execute successive formulation batches for self-emulsifying drug delivery systems (SEDDS). For paclitaxel it achieved a 50% high-performance hit rate versus 17% for Andromeda 1 and 2% for a wet-lab DoE campaign, identifying 12 formulations meeting all four target product profile objectives versus 6 and 0. A selected full-TPP formulation reached approximately 19% w/w apparent paclitaxel loading, about 3.3-fold higher than a published paclitaxel S-SEDDS, and an ablation showed structured evidence access increased mean AUC by 34%.